Peter Barris, an Insider in AVEO Pharmaceuticals, Inc. (AVEO), Acquired $2.12 million of the Company; National Asset Management Has Lifted Its Disney Walt Co (DIS) Stake

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Logo

National Asset Management Inc increased Disney Walt Co (DIS) stake by 12.69% reported in 2017Q4 SEC filing. National Asset Management Inc acquired 3,519 shares as Disney Walt Co (DIS)’s stock declined 8.57%. The National Asset Management Inc holds 31,252 shares with $3.36 million value, up from 27,733 last quarter. Disney Walt Co now has $152.43B valuation. The stock increased 1.68% or $1.67 during the last trading session, reaching $101.37. About 8.32 million shares traded or 0.69% up from the average. The Walt Disney Company (NYSE:DIS) has declined 11.59% since April 11, 2017 and is downtrending. It has underperformed by 23.14% the S&P500.

The Walt Disney Company (NYSE:DIS) Ratings Coverage

Among 39 analysts covering The Walt Disney Company (NYSE:DIS), 24 have Buy rating, 3 Sell and 12 Hold. Therefore 62% are positive. The Walt Disney Company had 153 analyst reports since July 24, 2015 according to SRatingsIntel. Bank of America maintained the stock with “Buy” rating in Wednesday, January 10 report. The stock of The Walt Disney Company (NYSE:DIS) has “Outperform” rating given on Tuesday, January 2 by Macquarie Research. The firm has “Market Perform” rating by Wells Fargo given on Tuesday, August 18. The firm has “Hold” rating given on Tuesday, February 6 by Jefferies. As per Monday, February 8, the company rating was maintained by Topeka Capital Markets. On Tuesday, July 26 the stock rating was downgraded by FBR Capital to “Market Perform”. The firm has “Hold” rating given on Tuesday, August 8 by Cowen & Co. The stock of The Walt Disney Company (NYSE:DIS) has “Hold” rating given on Friday, July 7 by Cowen & Co. GBH Insights maintained the stock with “Buy” rating in Wednesday, February 7 report. The company was maintained on Wednesday, January 31 by Morgan Stanley.

National Asset Management Inc decreased Voya Infrastructure Indls & (IDE) stake by 44,972 shares to 34,545 valued at $583,000 in 2017Q4. It also reduced Vanguard Whitehall Fds Inc (VYM) stake by 11,148 shares and now owns 9,558 shares. Alphabet Inc was reduced too.

Investors sentiment increased to 0.9 in 2017 Q4. Its up 0.01, from 0.89 in 2017Q3. It improved, as 58 investors sold DIS shares while 690 reduced holdings. 162 funds opened positions while 508 raised stakes. 896.07 million shares or 0.31% less from 898.84 million shares in 2017Q3 were reported. 10,170 are held by Dixon Hubard Feinour Brown Incorporated Va. 1St Source National Bank accumulated 83,405 shares or 0.74% of the stock. Alpha Cubed Invests Limited Liability Company has 1.05% invested in The Walt Disney Company (NYSE:DIS) for 74,886 shares. Connecticut-based Sustainable Growth Advisers Ltd Partnership has invested 1.35% in The Walt Disney Company (NYSE:DIS). Tradewinds Capital Mgmt Limited Liability has 5,074 shares for 0.27% of their portfolio. Kentucky Retirement Sys Ins Tru Fund invested 0.72% of its portfolio in The Walt Disney Company (NYSE:DIS). Dillon Assoc Inc owns 60,761 shares. Parthenon Limited Liability Company has invested 0.15% in The Walt Disney Company (NYSE:DIS). Exxonmobil Investment Mngmt Inc Tx reported 240,146 shares. 81,690 were accumulated by Columbia Asset Mngmt. 13,230 are held by Lau Associate Ltd Llc. Janney Mgmt Ltd, a Pennsylvania-based fund reported 5,642 shares. Silchester Intll Investors Llp reported 0.07% in The Walt Disney Company (NYSE:DIS). Summit Secs Group Ltd Liability Co has invested 0.78% in The Walt Disney Company (NYSE:DIS). Raymond James Advsrs accumulated 0.3% or 441,081 shares.

Since February 26, 2018, it had 0 insider purchases, and 1 insider sale for $194,780 activity. Shares for $194,780 were sold by LEWIS AYLWIN B on Monday, February 26.

Investors sentiment increased to 2.81 in 2017 Q4. Its up 1.49, from 1.32 in 2017Q3. It is positive, as 4 investors sold AVEO Pharmaceuticals, Inc. shares while 12 reduced holdings. 26 funds opened positions while 19 raised stakes. 59.55 million shares or 0.59% less from 59.90 million shares in 2017Q3 were reported. Alphaone Svcs Limited Liability Corporation reported 0% stake. Glg Partners Ltd Partnership reported 25,200 shares stake. State Street invested in 127,143 shares. Finemark National Bank & Trust & owns 10,000 shares. Point72 Asset Mgmt Lp has invested 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Spark Mgmt Limited Liability, a New York-based fund reported 268,200 shares. Victory Cap Inc reported 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Deer Vi Limited holds 100% or 675,242 shares. Bancorp Of America De invested in 6,000 shares. National Bank & Trust Of New York Mellon has 91,625 shares. New York-based 683 Cap Management Limited Liability Company has invested 0.59% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Edge Wealth Mngmt Limited Liability reported 10,000 shares stake. California Public Employees Retirement Sys holds 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 153,845 shares. Credit Suisse Ag invested 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Ra Cap holds 5.06 million shares.

Among 3 analysts covering AVEO Pharmaceuticals (NASDAQ:AVEO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AVEO Pharmaceuticals has $7 highest and $200 lowest target. $5.67’s average target is 133.33% above currents $2.43 stock price. AVEO Pharmaceuticals had 15 analyst reports since March 30, 2016 according to SRatingsIntel. The rating was initiated by Piper Jaffray with “Overweight” on Thursday, May 19. The firm earned “Buy” rating on Thursday, December 7 by FBR Capital. Piper Jaffray maintained the stock with “Buy” rating in Wednesday, August 9 report. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) earned “Buy” rating by Piper Jaffray on Thursday, March 29. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) earned “Buy” rating by FBR Capital on Tuesday, January 16. The firm has “Buy” rating by FBR Capital given on Thursday, March 22. The rating was maintained by FBR Capital with “Buy” on Monday, June 26. The stock has “Outperform” rating by FBR Capital on Wednesday, March 30. The rating was maintained by FBR Capital with “Buy” on Monday, February 12. Piper Jaffray upgraded the shares of AVEO in report on Monday, August 28 to “Buy” rating.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $374.59 million. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

The stock decreased 2.80% or $0.07 during the last trading session, reaching $2.43. About 2.84 million shares traded or 45.39% up from the average. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has risen 351.31% since April 11, 2017 and is uptrending. It has outperformed by 339.76% the S&P500.

Major shareholder, Peter Barris is the Aveo Pharmaceuticals Inc’s insider which bought shares of Aveo Pharmaceuticals Inc, 920,976 to be precise. The acquired shares were based on a market stock price per share of $2.3, with the investment valued at $2.12 million USD . The probability of this deal remaining disregarded is little because it’s big one, with Peter Barris now holding 17.28 million shares — that is 11.21% of the Company’s total market cap. This investment, which was filled on April 10, 2018 was made public in a document with the Security Exchange Commission.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Institutional Positions Chart